Literature DB >> 839438

9-nor-9beta-hydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity: comparisons with morphine.

A S Bloom, W L Dewey, L S Harris, K K Brosius.   

Abstract

The effects of (+/-)9-nor-9beta-hydroxyhexahydrocannabinol (beta-HHC) on tail-flick test activity and the accumulation of newly synthesized dopamine and norepinephrine were studied in the male albino mouse. The same parameters were also studied in naloxone-pretreated and morphine-tolerant mice. beta-HHC was about equipotent with morphine in the mouse tail-flick (ED50 = 7.12 mg/kg). The cannabinoid also produced dose-dependent increases in the accumulation of newly synthesized DA and NE. Pretreatment with 2 mg/kg of naloxone antagonized both the tail-flick activity and blocked the increases in catecholamine synthesis produced by beta-HHC. Cross-tolerance between beta-HHC and morphine did not exist in regard to either tail-flick activity or increased catecholamine synthesis. These studies suggest that beta-HHC may share some properties with the narcotic analgesics but that significant differences exist. Furthermore, these studies offer further evidence for the involvement of catecholamine containing neurons in the central mediation of the tail-flick response.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 839438

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Effects of GABAA receptors in nucleus cuneiformis on the cannabinoid antinociception using the formalin test.

Authors:  Junjie Chen; Parisa Hasanein; Alireza Komaki; Siamak Yari
Journal:  Psychopharmacology (Berl)       Date:  2021-03-13       Impact factor: 4.530

2.  Possible mediation of catecholaminergic pathways in the antinociceptive effect of an extract of Cannabis sativa L.

Authors:  S Ferri; E Cavicchini; P Romualdi; E Speroni; G Murari
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse.

Authors:  A S Bloom; W L Dewey
Journal:  Psychopharmacology (Berl)       Date:  1978-05-31       Impact factor: 4.530

Review 4.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 5.  Endocannabinoid mechanisms of pain modulation.

Authors:  Andrea G Hohmann; Richard L Suplita
Journal:  AAPS J       Date:  2006-11-17       Impact factor: 4.009

6.  Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects.

Authors:  W J Martin; A G Hohmann; J M Walker
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

7.  The cannabinoid receptor agonists, anandamide and WIN 55,212-2, do not directly affect mu opioid receptors expressed in Xenopus oocytes.

Authors:  George R Kracke; Sean P Stoneking; Joshua M Ball; Brandon M Tilghman; Carmen C Washington; Katherine A Hotaling; Joel O Johnson; Joseph D Tobias
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-25       Impact factor: 3.000

8.  Morphine and delta 9-tetrahydrocannabinol: two-way cross tolerance for antinociceptive and heart-rate responses in the rat.

Authors:  B Hine
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.